| Dolutegravir plus two different prodrugs of tenofovir to treat HIV WDF Venter, M Moorhouse, S Sokhela, L Fairlie, N Mashabane, ... New England Journal of Medicine 381 (9), 803-815, 2019 | 677 | 2019 |
| Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission GS Cooke, I Andrieux-Meyer, TL Applegate, R Atun, JR Burry, ... The lancet Gastroenterology & hepatology 4 (2), 135-184, 2019 | 543 | 2019 |
| Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis B Simmons, J Saleem, A Hill, RD Riley, GS Cooke Clinical Infectious Diseases 62 (6), 683-694, 2016 | 397 | 2016 |
| Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological … B Simmons, J Saleem, K Heath, GS Cooke, A Hill Clinical Infectious Diseases 61 (5), 730-740, 2015 | 336 | 2015 |
| Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries A Hill, S Khoo, J Fortunak, B Simmons, N Ford Clinical Infectious Diseases 58 (7), 928-936, 2014 | 303 | 2014 |
| Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial … WDF Venter, S Sokhela, B Simmons, M Moorhouse, L Fairlie, ... The lancet HIV 7 (10), e666-e676, 2020 | 259 | 2020 |
| Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-19 seroprevalence survey B Flower, JC Brown, B Simmons, M Moshe, R Frise, R Penn, ... Thorax 75 (12), 1082-1088, 2020 | 152 | 2020 |
| The road to elimination of hepatitis C: analysis of cures versus new infections in 91 countries AM Hill, S Nath, B Simmons Journal of virus eradication 3 (3), 117-123, 2017 | 151 | 2017 |
| Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a … A Sadeghi, A Ali Asgari, A Norouzi, Z Kheiri, A Anushirvani, M Montazeri, ... Journal of Antimicrobial Chemotherapy 75 (11), 3379-3385, 2020 | 130 | 2020 |
| The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19 G Eslami, S Mousaviasl, E Radmanesh, S Jelvay, S Bitaraf, B Simmons, ... Journal of Antimicrobial Chemotherapy 75 (11), 3366-3372, 2020 | 122 | 2020 |
| Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C A Hill, B Simmons, D Gotham, J Fortunak Journal of virus eradication 2 (1), 28-40, 2016 | 110 | 2016 |
| Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a … H Abbaspour Kasgari, S Moradi, AM Shabani, F Babamahmoodi, ... Journal of Antimicrobial Chemotherapy 75 (11), 3373-3378, 2020 | 109 | 2020 |
| Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: a randomised trial (DolPHIN-1 study) C Waitt, C Orrell, S Walimbwa, Y Singh, K Kintu, B Simmons, ... PLoS medicine 16 (9), e1002895, 2019 | 105 | 2019 |
| Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase MJ Siedner, MA Moorhouse, B Simmons, T de Oliveira, R Lessells, ... Nature communications 11 (1), 5922, 2020 | 76 | 2020 |
| SARS-CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (React 2): diagnostic accuracy study M Moshe, A Daunt, B Flower, B Simmons, JC Brown, R Frise, R Penn, ... bmj 372, 2021 | 75 | 2021 |
| Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes K McCann, S Shah, L Hindley, A Hill, A Qavi, B Simmons, C Serenata, ... Aids 35 (10), 1657-1665, 2021 | 72 | 2021 |
| Increased dolutegravir peak concentrations in people living with human immunodeficiency virus aged 60 and over, and analysis of sleep quality and cognition ER Elliot, X Wang, S Singh, B Simmons, JH Vera, RF Miller, C Fitzpatrick, ... Clinical Infectious Diseases 68 (1), 87-95, 2019 | 72 | 2019 |
| Minimum target prices for production of direct‐acting antivirals and associated diagnostics to combat hepatitis C virus N van de Ven, J Fortunak, B Simmons, N Ford, GS Cooke, S Khoo, A Hill Hepatology 61 (4), 1174-1182, 2015 | 65 | 2015 |
| Prevalence of hepatitis B and C infection in persons living with HIV enrolled in care in Rwanda J Umutesi, B Simmons, JD Makuza, D Dushimiyimana, A Mbituyumuremyi, ... BMC infectious diseases 17, 1-7, 2017 | 64 | 2017 |
| Lancet Gastroenterology & Hepatology Commissioners. Accelerating the elimination of viral hepatitis: a lancet Gastroenterology & hepatology commission GS Cooke, I Andrieux-Meyer, TL Applegate, R Atun, JR Burry, ... Lancet Gastroenterol Hepatol 4 (2), 135-184, 2019 | 60 | 2019 |
